Total revenue increases 11 percent to $26.4 million Mass cytometry revenue growth of 32 percent Total consumables revenue growth of 19 percent SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the second quarter
Providing more affordable full-length single-cell mRNA sequencing with industry-leading coverage and sensitivity for in-depth cellular characterization SOUTH SAN FRANCISCO, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies,
Pairing epigenetic profiling with T cell receptor sequencing at single-cell resolution to advance cancer, immunology and stem cell research SOUTH SAN FRANCISCO, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies, today
SOUTH SAN FRANCISCO, Calif. , July 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative life science company that develops, manufactures and markets multiparameter mass cytometry and proprietary microfluidics systems used in research and applied markets, announced today
SOUTH SAN FRANCISCO, Calif. , June 26, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of David King as Vice President, Research and Development, Genomics. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite , King
Joint offering enables acceleration of genomic panel design for translational and clinical disease research SOUTH SAN FRANCISCO, Calif. , June 07, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation announced today that it has entered into a co-marketing agreement with Genomenon to offer evidence-based
Standardizing human sample identification using automated genomic microfluidic systems that reduce hands-on time and cost per sample SOUTH SAN FRANCISCO, Calif. , June 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ Sample ID
SOUTH SAN FRANCISCO, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of May 8, 2018 , under Fluidigm's
SOUTH SAN FRANCISCO, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative life science company that develops, manufactures and markets multiparameter mass cytometry technology and proprietary microfluidics systems used in research and applied markets,
Product Innovations in Mass Cytometry and Genomics Total Revenue of $25.2 million , Genomics Revenue Growth of 18 Percent SOUTH SAN FRANCISCO, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the first quarter ended March 31, 2018 .
